After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

"Patients presenting with chronic diarrhea, blood in the stool, unexplained nausea and vomiting, or unexplained weight loss ...

Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's ...

Bristol Myers Squibb (BMS) has announced that its PD-1 immune checkpoint inhibitor Opdivo (nivolumab) has been approved by ...

Bristol Myers Squibb is making waves as a value stock darling, thanks to its low P/E and robust drug portfolio. The company ...

Louis, has been elected as the new Speaker of the House of Commons in Canada. Chosen by fellow MPs, he will moderate debates ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

Plenge currently works at PhRMA Foundation, as Director and Bristol Myers Squibb Co., as Chief Research Officer, Head-Research & EVP from 2019. Dr. Plenge also formerly worked at Translate Bio, Inc., ...

The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- ...

Bristol Myers Squibb is storming ASCO 2025 with data from over 80 studies covering 20+ cancer types, showcasing its oncology ...